DNA damage repair response is a crucial process for cancer prevention. One of the key regulators of this process is ataxia telangiectasia mutated (ATM) kinase, which modulates the p53 level by direct and indirect phosphorylation. Recent data showed that ATM also localizes at the centrosome, but the function remains elusive. TAX1BP2 was initially identified as a novel centrosomal protein that interacts directly with the human T-cell leukemia virus type 1 (HTLV-1)-encoded oncoprotein, Tax, and inhibits centrosome overduplication. Subsequently, TAX1BP2 was found to be a tumor suppressor in hepatocellular carcinoma, and accumulation of TAX1BP2 was observed upon chemotherapeutic drug treatment. Here, we provide evidence that TAX1BP2 is a direct phosphorylation substrate of ATM. The protein level of TAX1BP2 is significantly upregulated in response to DNA damaging agents. Serine-922 of TAX1BP2 is the phosphorylation site of ATM, and such phosphorylation modulates the protein stability, ubiquitination and tumor suppressor activity of TAX1BP2. Taken together, we demonstrate for the first time that TAX1BP2 is a novel effector of ATM in DNA damage response and delineated a new mechanism by which ATM stabilizes the tumor suppressor TAX1BP2.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third leading cause of cancer death worldwide. 1 Although surgical resection, liver transplantation and locoregional ablation are effective curative measures for HCC, most patients with advanced and inoperable HCC receive chemotherapy. 2 The centrosome is the microtubule-organizing center coordinating the microtubule network essential for cell shape, polarity, motility, intracellular transport, spindle formation and chromosome segregation. 3 Our previous study demonstrated that a centrosomal protein, Tax1 binding protein 2 (TAX1BP2 or TAXBP121), interacts with Tax, which is an oncogenic transcriptional activator encoded by the human T-cell leukemia virus type 1 (HTLV-1), and acts as an intrinsic block to centrosome overduplication. 4 We further showed that TAX1BP2 is a novel cyclin dependent kinase 2-regulated tumor suppressor in HCC, which activates the p38 MAPK/p53/p21 pathway, and is upregulated by chemotherapeutic agents that induce DNA damage. 5 However, the molecular mechanism underlying the regulation of TAX1BP2 in the DNA damage response is still poorly understood. Ataxia telangiectasia mutated (ATM) is a key regulator of DNA damage response. 6 Activation of ATM induces cell cycle arrest via the activation of p53. 7 Recent evidence suggests that ATM also translocates to centrosomes transiently, but the function is not fully understood. 8 In this study, we demonstrated that TAX1BP2 is a direct substrate of ATM, and phosphorylation of TAX1BP2 by ATM significantly suppresses the ubiquitinationmediated protein degradation leading to the stabilization of TAX1BP2. Taken together, our data provided the first evidence that ATM acts as a tumor suppressor in liver cancer by phosphorylating TAX1BP2 to maintain TAX1BP2's tumor suppressive activity.
RESULTS AND DISCUSSION
ATM activity was required for the upregulation of TAX1BP2 In our previous study, we showed that the TAX1BP2 protein level in HCC cells was significantly upregulated by the treatment with two chemotherapeutic agents, cisplatin and etoposide. 5 However, the mechanism for the TAX1BP2 upregulation is unclear. As activation of ATM is one of the hallmarks in DNA damage response, we speculated an involvement of ATM in the accumulation of TAX1BP2 upon treatment with chemotherapeutic agent. To explore this possibility, we treated HCC cell lines, SMMC-7721 and HepG2, with several DNA-damaging agents, cisplatin, etoposide and neocarzinostatin (NCS), together with a specific pharmacological inhibitor of ATM, KU-55933. 9 Treatment of cells with these agents significantly increased the protein level of TAX1BP2 and its downstream effector p53, whereas co-treatment with KU-55933 suppressed the TAX1BP2 and p53 upregulation ( Figure 1a and Supplementary Figure 1A) . However, the DNA damaging agents had no effect on the transcript level of TAX1BP2 (Figure 1b and Supplementary Figure 1B) . To investigate the temporal regulation of TAX1BP2 by ATM, SMMC-7721 cells were collected at different time points after cisplatin or etoposide addition. Phosphorylation of ATM at serine-1981 (S1981), a sign of ATM activation, 6 could be detected 1 h post treatment and the phosphorylation level increased progressively with time ( Figure 1c) . Accumulation of TAX1BP2 was also observed in a similar time course, consistent with the notion that ATM activity is required for TAX1BP2 upregulation in HCC cells. To rule out the possibility that ATM-induced TAX1BP2 accumulation is due to a non-specific effect of the pharmacological inhibitors, RNA interference was further used to specifically knockdown the ATM in SMMC-7721 cells. Compromising the expression of ATM by siRNA significantly suppressed the TAX1BP2 accumulation upon treatment with DNA-damaging agents (Figure 1d ), strongly 0 -GACUUUGGCUGUCAACUUUCG-3 0 ) or control (siControl, 5 0 -UAAGGCUAUGAAGAGAUAC-3 0 ) siRNA (Shanghai GenePharma, Shanghai, China) using Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) for 48 h. 5, 15 The transfected cells were treated with cisplatin (CIS; 2 mg/ml) or etoposide (ETO; 120 mM) for 16 h, or neocarzinostatin (NCS; 100 ng/ml) for 1 h before collection. Western blot analysis was performed with indicated antibodies. (e) SMMC-7721 cells were pre-treated with UCN-01 (0.2 mM, Merck) or Chk2 inhibitor II (Chk2 In; 5 mM, Merck) for 4 h followed by cisplatin (CIS; 2 mg/ml) or etoposide (ETO; 120 mM) for 16 h before collection. Western blot analysis was performed using the anti-p-CDC25A (S76), anti-CDC25A (Abcam, Cambridge, MA, USA), anti-p-p53 (S20) (Cell Signaling) and anti-b-actin antibodies. (f ) SMMC-7721 cells were transfected with Chk1 (siChk1-1, 5
0 -GGTGCCTATGGAGAAGTTC-3 0 ; siChk1-2, 5 0 -GAAGCAGUCG CAGUGAAGA-3'), Chk2 (siChk2-1, 5
0 -AATGTGTGAATGACAACTACT-3 0 ; siChk2-2, 5 0 '-GAACCUGAGGACCAAGAAC-3 0 ) or control (siControl) siRNA for 48 h. The transfected cells were then treated with cisplatin (CIS; 2 mg/ml) for 16 h before collection. Western blot analysis was performed with anti-Chk1 (G-4, Santa Cruz) and anti-Chk2 (clone 7, Millipore, Billerica, MA, USA) (kind gifts from Prof SW Tsao, Department of Anatomy, HKU) and anti-b-actin antibodies. Band intensity: TAX1BP2/b-actin, p-CDC25A/CDC25A or p-p53 (S20)/b-actin as indicated. Intensity in DMSO (0.1%) control was set as 1. Error bars, mean±s.d. of triplicate samples.
supporting the finding that TAX1BP2 induction in response to DNA damage is ATM dependent.
To examine whether the downstream effectors of ATM, Chk1 and Chk2 kinases are involved in regulating TAX1BP2, we suppressed Chk1 and Chk2 activities with their corresponding chemical inhibitors, UCN-01 and Chk2 inhibitor II. As shown in Figure 1e and Supplementary Figure 1C , treatment with these Chk inhibitors had no significant effect on the level of TAX1BP2 in cisplatin-or etoposide-treated SMMC-7721 cells. The effectiveness of these inhibitors was verified by the effective suppression of phosphorylation of the downstream targets of Chk1 and Chk2, CDC25A at serine-76 and p53 at serine-20, respectively (Figure 1e ). Furthermore, we used siRNA to specifically knockdown Chk1 or Chk2 and showed that the loss of these kinases had little impact on the protein level of TAX1BP2 (Figure 1f ). These results indicate that the Chk activity is not required for upregulation of TAX1BP2. Similar results were obtained using another HCC cell line, HepG2 (Supplementary Figures 1D and E) . Thus, our data supported a direct regulation of TAX1BP2 by ATM, and the effect of ATM on TAX1BP2 is not cell-line specific.
ATM-phosphorylated TAX1BP2 at the serine-922 (S922) site A previous genome-wide study of ATM substrates identified a phosphopeptide containing the serine-1619 residue of ciliary rootlet coiled-coil (CROCC or Rootletin). 10 As TAX1BP2 is an alternatively spliced isoform of ciliary rootlet coiled-coil, we speculated that ATM might regulate TAX1BP2 by phosphorylation at the cognate S922 residue with reference to its primary sequence. 4 In view of this, the in vitro kinase assay was performed to confirm the phosphorylation of TAX1BP2 at S922 by ATM. Wild-type (WT) or kinase-dead ATM was immunoprecipitated from HEK293T cells ectopically expressing a FLAG-tagged ATM WT or kinase-dead protein. 11 As indicated in Figure 2a (lanes 2-4 and 6-8), the ATM WT, but not ATM kinase-dead, significantly phosphorylated the bacterially purified p53 and a truncated fragment of TAX1BP2 (a.a.701-1039) in a dose-dependent manner. Interestingly, the ATM WT could only weakly phosphorylate the TAX1BP2 non-phosphorylatable mutant with the replacement of S922 with alanine (S922A) (Figure 2a , lane 5), confirming that S922 is one of the ATM phosphorylation sites on TAX1BP2 in vitro.
To further elucidate whether the ATM phosphorylation of TAX1BP2 occurs intracellularly, we transfected an expression construct of Myc-tagged TAX1BP2 WT or S922A mutant into SMMC-7721 cells and treated the cells with NCS in the presence or absence of KU-55933. After immunoprecipitation, their phosphorylation status was examined by western blotting with a phospho-specific (p-S/TQ) antibody that preferentially recognizes ATM substrates. As shown in Figure 2b , the p-S/TQ signal of WT was significantly enhanced upon treatment with NCS (comparing lane 2 with 1). On the contrary, the signal was almost completely abolished upon co-treatment with KU-55933 (comparing lane 4 with 2), strongly indicating that TAX1BP2 is an intracellular substrate of ATM. Furthermore, the phosphorylation level of WT was significantly higher than that of the S922A mutant (70% less than WT; Figure 2b , comparing lane 6 with 2) upon treatment with NCS, confirming that S922 is an intracellular ATM phosphorylation site. Similar results were also obtained using HEK293T cells (Supplementary Figure 2A) .
To further prove that ATM indeed interacts with TAX1BP2, confocal immunofluorescence staining of the endogenous proteins was performed using the anti-TAX1BP2 and phospho-specific anti-ATM (p-ATM) antibodies. Although we attempted to use the total ATM antibody for immunocytostaining, it was unsuccessful because of the low sensitivity and specificity. When SMMC-7721 cells were treated with NCS, a significant enhancement of p-ATM signal was observed in the nucleus (Figure 2c , comparing NCS with DMSO), suggesting that the anti-p-ATM antibody could specifically detect the phosphorylated form of ATM. Interestingly, specific p-ATM signals were also observed to colocalize with the endogenous TAX1BP2 and the centrosomal marker, g-tubulin, after the NCS treatment (Figure 2c ). The percentage of p-ATM and TAX1BP2 colocalization in a total of 30 randomly chosen cells was 100. The specificity of signal recognized by the anti-TAX1BP2 antibody was further confirmed by blocking the antibody with an antigen, TAX1BP2 (a.a.1-815), before immunocytostaining (Figure 2c, NCS þ A) . 5 Therefore, our data indicated that the activated form of ATM colocalizes with TAX1BP2 at the centrosomes.
Phosphorylation of TAX1BP2 by ATM suppressed the ubiquitination of TAX1BP2 To understand how the activation of ATM upregulates TAX1BP2, we examined whether the phosphorylation of TAX1BP2 at S922 by ATM affects the protein stability. Stable WT, nonphosphorylatable (S922A) S922A and phosphorylation mimetic (S922D) of TAX1BP2 expression clones were established in SMMC-7721 cells (Figure 4b ), and cell lysates were collected at different time points upon the addition of a translation inhibitor, cycloheximide, together with or without cisplatin. As shown in Figure 3a , the S922D protein was much more stable than WT and S922A. At 6th and 8th h post treatment, the S922D protein was still maintained at high levels (79.2% and 78.2%, respectively) as compared with WT (55.6% and 32.1%, respectively) and S922A (43.8% and 28.4%, respectively). However, when the stable WT and S922A clones were co-treated with cisplatin, the WT but not S922A protein was stabilized, implicating that the S922 phosphorylation of TAX1BP2 is important for the stabilization of TAX1BP2 induced by the DNA damage response. To rule out the possibility that the conversion of serine to alanine and aspartic acid may alter the protein stability by affecting the subcellular localization of TAX1BP2 protein, we performed co-immunofluorescence staining of TAX1BP2 WT and its mutants with g-tubulin. Our data showed that the S922 mutations had no effect on the centrosome localization of TAX1BP2 (Supplementary Figure 2B) , excluding the possibility that mutation of S922 might cause mis-localization of TAX1BP2. As it has been documented that ubiquitination/ proteasome-dependent degradation of p53 can be suppressed by ATM phosphorylation, 12 we wonder whether phosphorylation of TAX1BP2 by ATM at S922 can also stabilize TAX1BP2 by inhibiting its ubiquitination. We first examined whether ATM can suppress the proteasome-dependent degradation of TAX1BP2. Treatment of SMMC-7721 cells with cisplatin caused an accumulation of TAX1BP2 protein (Figure 3b , comparing lane 5 with 1), whereas co-treatment with KU-55933 suppressed the accumulation (Figure 3b, lane 7) . However, additional treatment of the cells with the proteasome inhibitor, MG-132, abolished the suppressive effect of KU-55933, causing an upregulation of TAX1BP2 (Figure 3b, lane 8) . Hence, activation of ATM in the DNA damage response suppresses protein degradation of TAX1BP2 via the proteasome pathway. Then, to investigate whether the phosphorylation of TAX1B2 by ATM at S922 can inhibit the polyubiquitination of TAX1BP2, a ubiquitination assay was performed by co-transfecting HEK293T cells with constructs of TAX1BP2 WT, S922A or S922D and FLAG-tagged ubiquitin, and subsequently treated with MG-132. As shown in Figure 3c , the polyubiquitination level of the S922D mutant (lane 9) was significantly lower than that of WT and S922A mutant (lanes 8 and 10, respectively), suggesting that phosphorylation at S922 may suppress the polyubiquitination of TAX1BP2. To further investigate whether the polyubiquitination of TAX1BP2 is ATM dependent, HEK293T cells were transfected with constructs of TAX1BP2 WT and FLAG-ubiquitin and treated with NCS in the presence or absence of KU-55933. Consistently, NCS treatment significantly reduced the polyubiquitination level of TAX1BP2 (Figure 3d , comparing lane 4 with 3), whereas co-treatment with KU-55933 markedly restored the polyubiquitination (Figure 3d , lane 5), supporting the finding that ATM activity is required for suppressing the polyubiquitination of TAX1BP2. It is known that Figure 2 . Phosphorylation of TAX1BP2 by ATM at S922. (a) Left: FLAG-ATM WT or FLAG-ATM kinase-dead protein was immunoprecipitated from HEK293T cells (American Type Culture Collection, Manassas, VA, USA) using the anti-FLAG monoclonal G1 affinity resin (Genescript, Piscataway, NJ, USA) after transfection with the expression constructs (gifts of Prof Kastan, Addgene plasmids #31985 and #31986, respectively) by Lipofectamine2000 and detected by western blot analysis with rabbit anti-FLAG antibody (Sigma-Aldrich). Top right: Bacterial purified proteins of His-TAX1BP2 (a.a.701-1039) and S922A mutant, which was created by site-directed mutagenesis using primers of 5 0 -GAGCGAGCTCCGGGCCGCC CAGGAGAAGATCAGC-3 0 and 5 0 -GCTGATCTTCTCCTGGGCGGCCCGGAGCTCGCTC-3 0 , were incubated with the immunoprecipitated ATM in the in vitro kinase assay as described previously. 5, 16 The GST-p53 protein was used as a positive control. 2X, double amount of FLAG-ATM WT protein was used. Autoradiography was shown. Bottom right: The loading of proteins was visualized by Coomassie blue staining. (b) SMMC-7721 cells were transfected with constructs expressing TAX1BP2 WT or S922A mutant using Fugene6. At 16 h post transfection, cells were treated with KU-55933 (10 mM) for 4 h followed by neocarzinostatin (NCS; 100 ng/ml) for 1 h. Cells were then collected for immunoprecipitation with anti-Myc (9E10, Santa Cruz) antibody, and western blot analysis using the anti-phospho-(S/T) ATM/ATR substrate (S*/T*QG) (P-S/T 2 -100, Cell Signaling) and antiMyc (A14, Santa Cruz) antibodies was performed. Band intensity: p-S/TQ/total immunoprecipitated TAX1BP2. Intensity in lane 2 was set as 1. Input lysates were analyzed by western blot with the anti-phospho-ATM (S1981), anti-ATM, anti-Myc (9E10) and anti-b-actin antibodies. (c) SMMC-7721 cells were treated with DMSO (0.1%) or neocarzinostatin (NCS; 100 ng/ml) for 1 h. Endogenous TAX1BP2 or centrosomes (green), phospho-ATM (red) and nucleus (blue) were stained with the anti-TAX1BP2 or anti-g-tubulin (GTU-88, Sigma-Aldrich), anti-phospho-ATM (S1981) antibodies and DAPI (0.5 mg/ml, Invitrogen), respectively. The TAX1BP2 antigen (A; a.a.1-815) was used for pre-incubation with the anti-TAX1BP2 antibody in a ratio of 1 mg to 1 ml, respectively, before immunocytostaining. 5, 15 The insets, from top to bottom, show a higher magnification of TAX1BP2 or centrosomes, phospho-ATM and merged image as specified by the dashed-line box. A 100% colocalization of phospho-ATM and TAX1BP2 was observed in all of the 30 randomly chosen cells. ms, mouse. rb, rabbit. Scale bars, 5 mm.
the K48-linkage polyubiquitination is responsible for protein degradation signaling. 13 To determine the endogenous level of K48-linkage polyubiquitination of TAX1BP2, a ubiquitination assay was performed by treating the stable expression clones of TAX1BP2 WT, S922A and S922D with MG-132, together with or without cisplatin. As shown in Figure 3e , the level of polyubiquitin chains linked to the S922D mutant (lane 4) was significantly lower than that of the WT and S922A mutant (lanes 2 and 3, , S922A (SA-C1) or S922D (SD-C1) mutant were established as previously described. 5 In brief, SMMC-7721 cells were separately transfected with the pCMV-Tag3C vector and pCMV-Tag3C constructs of TAX1BP2 WT, S922A and S922D mutants using Fugene6. After 24 h, stable expressing clones were selected by medium supplemented with 0.8 mg/ml of G418 (Invitrogen). The construct of S922D mutant was created by site-directed mutagenesis using primers of 5 0 -GAGCGAGCTCCGGGCCGACCAGGAGAAGATCAGC-3 0 and 5 0 -GCTGATCTTCTCCTGGTCGGCCCGGAGCTCGCTC-3 0 . The stable expressing cells were treated with cycloheximide (CHX; 100 ng/ml, Merck) in the presence or absence of cisplatin (CIS; 2 mg/ml). The cell lysates were collected at different time points for western blot analysis using the anti-Myc (9E10) and anti-b-actin antibodies. Right: Band intensity of TAX1BP2 was normalized with b-actin and the ratio at 0 h was set as 100%. for 2 h and finally with neocarzinostatin (NCS; 100 ng/ml) for 1 h. (e) Stable SMMC-7721 cell lines, WT-C1, SA-C1 and SD-C1 were treated with MG-132 (20 mM) for 6 h followed by cisplatin (CIS; 2 mg/ml) for 16 h. The lysates were then immunoprecipitated with anti-c-Myc agarose conjugate and detected using the anti-K48-linkage-specific polyubiquitination (Cell Signaling) antibody in western blot analysis. Bottom: Amount of immunoprecipitated Myc-tagged TAX1BP2 was detected by western blot analysis with anti-Myc (9E10) antibody as a loading control. Band intensity: Ubiquitinated TAX1BP2 with K48-linkage/Myc-TAX1BP2. Intensity in lane 2 was set as 1.
respectively). In addition, when the stable clones were treated with cisplatin, polyubiquitination of the WT had a much greater suppression (Figure 3e , comparing lane 6 with 2, reduced by 68.0%) than that of the S922A and S922D mutants (comparing lane 7 with 3 and 8 with 4, reduced by 20.5% and 10.0%, respectively), indicating that S922 phosphorylation of TAX1BP2 is important for the inhibition of K48-linkage polyubiquitination of TAX1BP2 in the DNA damage response. Taken together, our results strongly indicated that phosphorylation of TAX1BP2 at S922 by ATM stabilizes TAX1BP2 via suppression of ubiquitin/ proteasome degradation of TAX1BP2.
Phosphorylation of S922 sustained the tumor suppressor activity of TAX1BP2 Our previous study has demonstrated that TAX1BP2 can upregulate p53 by activating p38, which is believed to contribute significantly to its tumor suppressor activity. 5 To investigate the functional impact of ATM phosphorylation on TAX1BP2, the construct expressing HA-tagged p38 was co-transfected with WT, S922D or S922A mutant of TAX1BP2 into SMMC-7721 cells, and the ability to activate p38 was examined. As shown in Figure 4a , both WT and S922A mutant could significantly upregulate the activating phosphorylation of p38 as compared with the vector control. However, the presence of S922D mutant resulted in the highest level of p38 phosphorylation. In the stable WT and S922A clones, the levels of endogenous p38 phosphorylation were significantly higher than those in the stable vector clones (Figure 4b ). Stable expression of S922D mutant caused the highest level of p38 phosphorylation, suggesting that ATM phosphorylation sustains the p38-activating activity of TAX1BP2. To further elucidate whether the S922D mutant is a better activator of p53, the p53-responsive luciferase reporter assay was performed. When WT, S922A or S922D mutant and the p53-responsive luciferase reporter were co-transfected into SMMC-7721 cells, all TAX1BP2 constructs significantly activated the luciferase activity in a dosage-dependent manner ( Figure 4c ). As compared with WT and S922A, the S922D mutant exhibited the highest level of p53 activation. To further examine whether ATM phosphorylation has an important role in the tumor suppressor activity of TAX1BP2, a colony formation assay was performed. As shown in Figure 4d , all TAX1BP2 constructs significantly suppressed the colony formation, with the S922D mutant displaying the greatest inhibition, indicating that the S922D mutant is the strongest suppressor of cell growth among all. Similar p53-activating and suppression of colony formation results were obtained using HepG2 cells (Supplementary Figures 2C and D,  respectively) . Therefore, the tumor suppressor function of TAX1BP2 is sustained by ATM phosphorylation. The role of ATM in HCC is still largely unknown, although a previous study using ATM knockout mice demonstrated that a loss of ATM delayed the onset of HCC induced by the carcinogen, diethylnitrosamine.
14 Although it remains to be determined how the tumorigenic pathway of diethylnitrosamine interacts with ATM, our data, however, provided the first evidence that ATM can also have a tumor suppressor role in hepatocarcinogenesis in vitro. transfected with p53 luciferase reporter together with an increasing amount of TAX1BP2 WT, S922A or S922D constructs for the luciferase reporter assay as described previously. 5 Vector (pCMV-Tag3C) and p53 were used as the negative and positive controls, respectively. The experiment was performed at least twice independently. Insets: western blot for protein expression. *Po0.05 (Student t test) compared with the vector control. (d) SMMC-7721 cells were transfected with constructs expressing TAX1BP2 WT, S922A or S922D mutant for the colony formation assay as described previously. 5, 15 Insets: western blot for protein expression. Vector (pCMV-Tag3C) and mock transfection (MT) were used as the positive and negative controls, respectively. *Po0.04, **Po0.01 (Student t test) compared with the vector control. Error bars, mean±s.d. of triplicate samples.
